Kanghong Pharmaceutical: Stock incentive plan conditions met

Chengdu Kanghong Pharmaceutical Group (SZSE:002773) announced that the conditions for the first exercise period of its 2023 Stock Appreciation Rights Incentive Plan have been met. A total of one eligible participant is now able to exercise rights for 40,000 stock appreciation rights, representing 0.0043% of the company's total share capital as of May 23, 2025. The exercise price is set at CNY 15.92 per share, adjusted from the initial CNY 16.52 due to equity distribution. The company clarified that this exercise will not affect the total share capital and is expected to have minimal impact on earnings per share and return on equity. The board of directors approved the adjustments, aligning with regulations and the incentive plan's guidelines.